Revision history of "Development of the research infrastructure of the Lublin Diagnostic Centre" (Q104101)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

11 October 2024

  • curprev 03:4703:47, 11 October 2024DG Regio talk contribs 81,110 bytes +3 Changed label, description and/or aliases in pt
  • curprev 03:4703:47, 11 October 2024DG Regio talk contribs 81,107 bytes −2 Set a claim value: summary (P836): O principal objectivo do projecto é aumentar a competitividade da empresa no mercado internacional, alargando o âmbito da I & D realizada para outras entidades, principalmente empresas farmacêuticas e biotecnológicas globais. Este objectivo será alcançado através da aquisição de infra-estruturas de investigação e desenvolvimento: O meu e dedicado. Os estudos planeados incluem o processo de criação de linhas celulares necessárias para o tratamento de...

7 March 2024

15 January 2024

12 June 2023

24 May 2023

2 March 2023

25 October 2022

21 October 2022

2 July 2022

  • curprev 12:3812:38, 2 July 2022DG Regio talk contribs 76,302 bytes +49,300 Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, it, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, sl, cs, lt, lv, bg, hu, ga, sv, et,

18 January 2022

15 January 2022

17 December 2021

7 December 2021

1 December 2021

  • curprev 08:5808:58, 1 December 2021DG Regio talk contribs 16,298 bytes +2,654 Created claim: summary (P836): L’objectif principal du projet est d’accroître la compétitivité de l’entreprise sur le marché international en élargissant la portée des travaux de R & D réalisés pour d’autres entités, principalement des entreprises pharmaceutiques et biotechnologiques mondiales. Cet objectif sera atteint par l’achat d’infrastructures de R & D: propre et dédié. Les études prévues comprennent le processus de création de lignées cellulaires nécessaires au traitem...
  • curprev 08:5808:58, 1 December 2021DG Regio talk contribs 13,644 bytes +142 Changed label, description and/or aliases in fr: translated_label

29 October 2020

17 October 2020

  • curprev 16:2116:21, 17 October 2020DG Regio talk contribs 13,941 bytes +133 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 16:2116:21, 17 October 2020DG Regio talk contribs 13,808 bytes −110 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 16:2116:21, 17 October 2020DG Regio talk contribs 13,918 bytes +2,445 Created claim: summary (P836): The key objective of the project is to increase the competitiveness of the company on the international market by broadening the scope of R & D carried out for other entities, mainly global pharmaceutical and biotechnology companies. This objective will be achieved by purchasing infrastructure for research and development: my own and dedicated. The planned studies include the process of creating cell lines necessary for the treatment of various...
  • curprev 16:2116:21, 17 October 2020DG Regio talk contribs 11,473 bytes −1,983 Removed claim: summary (P836): The key objective of the project is to increase the competitiveness of the company on the international market by extending the scope of R & D work carried out in favour of other entities, mainly global pharmaceutical and biotech companies. This will be achieved through the purchase of infrastructure for research and development: own and dedicated. The planned studies include the process of creating the cell lines necessary for treating differ...

23 September 2020

22 June 2020

10 June 2020

7 June 2020

26 March 2020

6 March 2020

  • curprev 09:5809:58, 6 March 2020DG Regio talk contribs 12,166 bytes +1,983 Created claim: summary (P836): The key objective of the project is to increase the competitiveness of the company on the international market by extending the scope of R & D work carried out in favour of other entities, mainly global pharmaceutical and biotech companies. This will be achieved through the purchase of infrastructure for research and development: own and dedicated. The planned studies include the process of creating the cell lines necessary for treating differen...

24 February 2020

18 February 2020

31 January 2020

14 January 2020